CureVac (Nasdaq: CVAC) is a global biopharmaceutical company in the field of messenger RNA
(mRNA) technology, with more than 20 years of expertise in developing, optimizing, and
manufacturing this versatile biological molecule for medical purposes. The principle of CureVac’s
proprietary technology is the use of optimized mRNA as a data carrier to instruct the human
body to produce its own proteins capable of fighting a broad range of diseases. In July 2020,
CureVac entered in a collaboration with GSK to jointly develop new products in prophylactic
vaccines for infectious diseases based on CureVac’s second-generation mRNA technology. This
collaboration was later extended to the development of second-generation COVID-19 vaccine
candidates, and modified mRNA vaccine technologies. Based on its proprietary technology,
CureVac has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer
therapies, antibody therapies, and the treatment of rare diseases. CureVac N.V. has its
headquarters in Tübingen, Germany, and has more than 1,100 employees across its sites in
Germany, the Netherlands, Belgium, Switzerland, and the U.S.